MEDAREX INC
10-Q, EX-27, 2000-08-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: MEDAREX INC, 10-Q, 2000-08-14
Next: ADDVANTAGE TECHNOLOGIES GROUP INC, 10QSB, 2000-08-14



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
financial statements for the six months ended June 30, 2000 and is qualified in
its entirety by reference in such statements.
</LEGEND>
<MULTIPLIER>                               1,000

<S>                             <C>
<PERIOD-TYPE>                              6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                         149,226
<SECURITIES>                                   222,822
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               383,024
<PP&E>                                           8,660
<DEPRECIATION>                                 (5,192)
<TOTAL-ASSETS>                                 427,021
<CURRENT-LIABILITIES>                           11,042
<BONDS>                                              0
                                0
                                          0
<COMMON>                                           358
<OTHER-SE>                                     412,110
<TOTAL-LIABILITY-AND-EQUITY>                   427,021
<SALES>                                            113
<TOTAL-REVENUES>                                 5,242
<CGS>                                               54
<TOTAL-COSTS>                                   23,219
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   2
<INCOME-PRETAX>                                (9,579)
<INCOME-TAX>                                       300
<INCOME-CONTINUING>                            (9,879)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (9,879)
<EPS-BASIC>                                     (0.28)
<EPS-DILUTED>                                   (0.28)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission